Management of Women With Phenylalanine Hydroxylase Deficiency (Phenylketonuria): ACOG Committee Opinion, Number 802
- PMID: 32217978
- DOI: 10.1097/AOG.0000000000003768
Management of Women With Phenylalanine Hydroxylase Deficiency (Phenylketonuria): ACOG Committee Opinion, Number 802
Abstract
Phenylalanine hydroxylase (PAH) deficiency is an autosomal recessive disorder of phenylalanine metabolism that is characterized by insufficient activity of PAH, a hepatic enzyme. Throughout this document, PAH deficiency is used instead of the older nomenclature of phenylketonuria, in order to reflect the spectrum of PAH deficiency and in accordance with the terminology established by the American College of Medical Genetics and Genomics. Aspects of PAH deficiency management that are particularly relevant to obstetrician-gynecologists or other obstetric care providers include the prevention of embryopathy associated with maternal hyperphenylalaninemia and PAH deficiency and the risk of genetic transmission of PAH deficiency. Family planning and prepregnancy counseling are recommended for all reproductive-aged women with PAH deficiency. The fetal brain and heart are particularly vulnerable to high maternal concentrations of phenylalanine. The crucial role played by maternal dietary restriction before and during pregnancy should be stressed in counseling patients with PAH deficiency; the goal should be to normalize blood phenylalanine levels (less than 6 mg/dL) for at least 3 months before becoming pregnant and to maintain at 2-6 mg/dL during pregnancy, in order to optimize developmental outcomes for the fetus. Although phenylalanine levels are increased in the breast milk of patients with PAH deficiency, breastfed infants who do not have PAH deficiency have normal enzyme levels and no dietary restriction. Breastfeeding is safe for infants born to women who have PAH deficiency provided the infants do not have PAH deficiency. Coordinated medical and nutritional care, as well as follow-up with the patient's metabolic geneticist or specialist, are important in the postpartum period. Because newborns with PAH deficiency appear normal at birth and early detection can improve developmental outcomes for children, newborn screening for PAH deficiency is mandated in all states. This Committee Opinion has been revised to include updates on advances in the understanding and management of women with PAH deficiency and recommendations on prepregnancy counseling, serial fetal growth assessments, and fetal echocardiography.
Similar articles
-
Management of Women With Phenylalanine Hydroxylase Deficiency (Phenylketonuria): ACOG Committee Opinion Summary, Number 802.Obstet Gynecol. 2020 Apr;135(4):987-988. doi: 10.1097/AOG.0000000000003769. Obstet Gynecol. 2020. PMID: 32217972
-
ACOG Committee Opinion No. 449: Maternal phenylketonuria.Obstet Gynecol. 2009 Dec;114(6):1432-1433. doi: 10.1097/AOG.0b013e3181c6f93d. Obstet Gynecol. 2009. PMID: 20134300
-
Similarities and differences in key diagnosis, treatment, and management approaches for PAH deficiency in the United States and Europe.Orphanet J Rare Dis. 2020 Sep 25;15(1):266. doi: 10.1186/s13023-020-01541-2. Orphanet J Rare Dis. 2020. PMID: 32977849 Free PMC article. Review.
-
Nutritional management of phenylalanine hydroxylase (PAH) deficiency in pediatric patients in Canada: a survey of dietitians' current practices.Orphanet J Rare Dis. 2019 Jan 8;14(1):7. doi: 10.1186/s13023-018-0978-0. Orphanet J Rare Dis. 2019. PMID: 30621767 Free PMC article.
-
Phenylalanine tolerance in three phenylketonuric women pregnant with fetuses of different genetic PKU status.J Inherit Metab Dis. 2009 Dec;32 Suppl 1:S1-4. doi: 10.1007/s10545-008-0910-1. Epub 2009 Feb 7. J Inherit Metab Dis. 2009. PMID: 19194782
References
-
- Vockley J, Andersson HC, Antshel KM, Braverman NE, Burton BK, Frazier DM, et al. Phenylalanine hydroxylase deficiency: diagnosis and management guideline. American College of Medical Genetics and Genomics Therapeutics Committee [published erratum appears in Genet Med 2014;16:356]. Genet Med 2014;16:188–200.
-
- Brown AS, Fernhoff PM, Waisbren SE, Frazier DM, Singh R, Rohr F, et al. Barriers to successful dietary control among pregnant women with phenylketonuria. Genet Med 2002;4:84–9.
-
- Perez-Duenas B, Cambra FJ, Vilaseca MA, Lambruschini N, Campistol J, Camacho JA. New approach to osteopenia in phenylketonuric patients. Acta Paediatr 2002;91:899–904.
-
- Maternal phenylketonuria. Committee on Genetics. Pediatrics 2008;122:445–9.
-
- Lenke RR, Levy HL. Maternal phenylketonuria and hyperphenylalaninemia. An international survey of the outcome of untreated and treated pregnancies. N Engl J Med 1980;303:1202–8.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical